Picture of Cytek Biosciences logo

CTKB Cytek Biosciences Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Annual cashflow statement for Cytek Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line3.032.48-12.1-6.02-66.5
Depreciation
Deferred Taxes
Non-Cash Items8.7222.721.619.425.5
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital-8.36-39.9-10.27.71-4.79
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities4.63-12.25.2825.4-4.69
Capital Expenditures-4.36-9.87-4.83-3.73-4.19
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items-16.6-46-89.1-79.214.3
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities-21-55.9-93.9-8310.1
Financing Cash Flow Items-0.209-0.419-0.554-0.669
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities2145.51-41.8-15.8-13.4
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash198-65.1-132-68.9-7.89